Loading company…
REMUUN develops therapeutic antibodies using its MEGA platform.
REMUUN uses its platform to develop monoclonal antibodies, with a focus on oncology. It works with biotechnology and pharmaceutical companies on antibody development. Based in Zurich, Switzerland, it raised CHF 150,000 from Venture Kick in March 2025.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in